Quantcast

Latest Trubion Stories

2009-02-03 15:00:00

SEATTLE, Feb. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present a corporate update and an overview of the company at two upcoming investor conferences in February and March: -- Feb. 10: BIO CEO & Investor Conference at the Waldorf Astoria, 301 Park Ave., in New York City. Peter Thompson, M.D., FACP, president, CEO and chairman, is scheduled to present at 9 a.m. EST. A replay of the webcast will be available one...

2008-10-03 09:00:38

Research and Markets (http://www.researchandmarkets.com/research/ab4b51/whos_developing_w) has announced the addition of the "Who's Developing What in Global Biopharmaceuticals?" report to their offering. A critical assessment of 50 leading companies, their research, products, partners and performance. The biopharmaceutical R&D sector is taking an ever more important role in the minds of industry and investors. The potential to fundamentally alter treatment regimes and cure,...

2008-09-11 15:00:40

SEATTLE, Sept. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. , today announced that the Opposition Division (OD) of the European Patent Office (EPO) has revoked Genentech and Biogen Idec's European Patent 1176981, in its entirety. This patent was generally directed to the use of an anti-CD20 antibody for the treatment of rheumatoid arthritis (RA). The revocation was the result of an opposition proceeding brought by Trubion and several other parties. The OD, presiding in oral...

2008-08-18 18:00:48

SEATTLE, Aug. 18 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced that Scott C. Stromatt, M.D., has been appointed Trubion's senior vice president and chief medical officer (CMO). Dr. Stromatt replaces Daniel J. Burge, M.D., who will be resigning his position with the company for personal reasons in late August 2008. Dr. Stromatt has extensive experience related to the development and commercialization of novel therapies. Most recently, he was executive vice...

2008-06-16 18:00:39

SEATTLE, June 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced presentation of data at the 2008 Annual European Congress of Rheumatology meeting in Paris demonstrating that repeat administration with TRU-015, Trubion's lead candidate for the treatment of rheumatoid arthritis (RA), continues to produce persistent responses on the American College of Rheumatology (ACR) criteria and consistent pharmacodynamic (PD) effects. In addition, preclinical data presented at the...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related